Coeptis Therapeutics Inc. - COEP Enterprise Value-to-Revenue Multiple

At the current testing stage, Coeptis Therapeutics (COEP) relies on external contractors under strict internal supervision. The GURU.Markets system displays the price-to-sales multiple trend, where the 55301.47 mark serves as the current indicator. The company is developing safe alternatives to chemotherapy based on NK cells, while maintaining significant market influence in the resistant leukemia therapy segment.
COEP (Coeptis Therapeutics Inc.): analytical breakdowns and indicator data

This multiple determines the total enterprise value, including debt and subtracting cash, relative to annual sales to identify fundamental overvaluation of the asset. In the context of the non-cyclical drug development of Coeptis Therapeutics (COEP), changes in the EV/Sales multiple allow for the assessment of market expectations regarding clinical success independently of macroeconomics, helping investors identify entry points when the company's scientific potential is undervalued.